SkinBioTherapeutics Acquires Yorkshire Firm BTS

SkinBioTherapeutics has strategically expanded its business, demonstrating a transformation through acquisitions. The firm announced the acquisition of Bio-Tech Solutions Ltd, a Yorkshire-based company, for £1.25 million, marking its second acquisition within a year. This deal was funded through a shareholder loan, additional fundraising, and reserves.

• The acquisition includes Bio-Tech Solutions’ expertise in health and hygiene product manufacturing with 23 employees transitioning to SkinBioTherapeutics.
• Bio-Tech Solutions’ established revenue stream of £2.1 million and £500,000 EBITDA supports the strategic growth of SkinBioTherapeutics.
• The acquisition promises cost synergies and positions the company to develop advanced topical creams and capsules.
• CEO Stuart Ashman confirms the acquisition advances the firm’s aim to transform and supports future product development.

SkinBioTherapeutics, a burgeoning enterprise in the life sciences sector, has fortified its business strategy by acquiring Bio-Tech Solutions Ltd (BTS), a manufacturer and supplier of health, hygiene, and personal care products. The £1.25 million acquisition was facilitated through a loan from key shareholder David Brierwood, complemented by a fundraise of £250,000 and the company’s reserves.

Bio-Tech Solutions, located in Driffield, Yorkshire, brings a team of 23 employees skilled in manufacturing, packaging, formulation, and regulatory affairs into the fold. The firm has shown robust financial health with revenues of £2.1 million and an EBITDA of approximately £500,000 for the fiscal year ending June.

The transaction aligns with SkinBioTherapeutics’ strategy to generate immediate and long-term benefits. The integration of BTS is expected to bring cost synergies and provide a platform for future advancements in topical creams and oral healthcare products. Stuart Ashman, CEO of SkinBioTherapeutics, highlighted that this move would expand the company’s product portfolio while ensuring a stable production line backed by a regulatory-approved facility.

Ashman expressed confidence in the acquisition stating, “This is the second acquisition we have made as part of our buy and build strategy… we gain access to an important and varied customer base in the healthcare space with an excellent team which we intend to retain.” He affirmed that this transaction supports ongoing efforts to build a solid scientific and financial foundation for the company.